Reaffirming Affymetrix at Neutral - Analyst Blog
February 14 2012 - 6:15AM
Zacks
We retain our Neutral rating on
genetic products maker Affymetrix (AFFX) following
its tepid fourth-quarter fiscal 2011 results which missed the Zacks
Consensus Estimates. Its loss per share of 21 cents for the quarter
was higher than the Zacks Consensus Estimate of a loss of 7
cents.
Sales declined at a double-digit
clip, hurt by lower product revenues, and also missed the Zacks
Consensus Estimate. The California-based company witnessed declines
across its consumable and instrument businesses in the quarter,
resulting in a 18% decline in product revenues.
Both DNA and RNA sales declined in
the quarter. Gross margin dipped year over year, impacted by volume
absorption and unfavorable mix.
Affymetrix is a leading provider of
microarray-based products and services to the global research
community. Along with Illumina Inc. (ILMN), it is
one of the two major providers of microarray technologies,
primarily used in the field of genetic research. Affymetrix holds a
leading position in the gene expression products and services
market.
Affymetrix is expanding its
customer base through new product launches and strategic alliances.
Moreover, the company is pursuing a number of strategies (including
expansion into new markets) aimed at expanding its top line.
Affymetrix is shifting its R&D
focus from discovery and exploration markets to the faster-growing
validation and routine testing markets. The company reckons
cytogenetics and cancer research as promising areas for expansion,
representing market opportunities of roughly $200 million and $500
million, respectively.
The company has realigned its
operation into a number of business units including gene
expression, genetic analysis, life science reagents and clinical
diagnostics. The structural changes are expected to streamline its
decision-making process while improving customer focus and
accountability.
Affymetrix has also taken up
various steps to stabilize its expression business. Moreover, the
company expects its genetic analysis and clinical diagnostic
business to grow at least 20% in 2012, driven by its cytogenetics
program and increased traction of its Axiom genotyping
platform.
We are also encouraged by the
company’s move to buy privately-held eBioscience, a global leader
in immunology and oncology flow cytometry reagents. The acquisition
will significantly boost its foothold in the fast-growing
immunology, oncology and translational medicine markets,
representing an annual opportunity nearing $3 billion.
However, Affymetrix is operating in
an intensely competitive industry and faces risks associated with
lower R&D spending by its customers due to a soft economy and
government actions including budget cuts.
Affymetrix is exposed to a volatile
funding environment. The company has been beset by uncertainties
surrounding National Institutes of Health (“NIH”) funding. Decline
in government research grants may substantially affect the
company’s revenues. Affymetrix currently retains a Zacks #5 Rank,
which translates into a short-term “Strong Sell”
recommendation.
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
ILLUMINA INC (ILMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2023 to Aug 2024